Jovanna Baptista Selected Research

BES

1/2022

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jovanna Baptista Research Topics

Disease

3	Hereditary Angioedemas 11/2018 - 01/2015
3	Angioedema 09/2017 - 01/2015
1	von Willebrand Diseases (von Willebrand's Disease) 01/2022
1	Hemorrhage 01/2022
1	Hereditary Angioedema Types I and II 11/2018
1	Injection Site Reaction 11/2018
1	Dizziness (Lightheadedness) 11/2018
1	Cardiac Arrhythmias (Arrythmia) 01/2015
1	Chest Pain (Chest Pains) 01/2015
1	Anemia 08/2008
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 08/2008
1	Iron Deficiencies 08/2008
1	Chronic Renal Insufficiency 08/2008
1	Thrombosis (Thrombus) 12/2005
1	Venous Thrombosis (Deep-Vein Thrombosis) 12/2005
1	Neoplasms (Cancer) 01/2005
1	Margins of Excision 01/2005

Drug/Important Bio-Agent (IBA)

2	lanadelumabIBA 11/2018 - 01/2017
2	Plasma KallikreinIBA 11/2018 - 01/2017
2	Monoclonal AntibodiesIBA 11/2018 - 01/2017
2	icatibantIBA 09/2017 - 01/2015
1	von Willebrand FactorIBA 01/2022
1	BESIBA 01/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2017
1	Bradykinin B2 ReceptorIBA 09/2017
1	IronIBA 08/2008
1	Ferrosoferric Oxide (Magnetite)FDA Link 08/2008
1	GadoliniumIBA 12/2005
1	interleukin-24 (ST16)IBA 12/2005
1	Capsules (Microcapsules)IBA 01/2005

Therapy/Procedure

2	Therapeutics 11/2018 - 01/2017